Want to join the conversation?
$AMGN's total revenues for 1Q16 increased by 10% from last year, with 7% product sales growth driven by rheumatoid arthritis treating drug Enbrel, osteoporosis drugs Prolia and XGEVA, as well as long-acting dialysis drug Aranesp, Neulasta (pegfilgrastim), and multiple myeloma drug Kyprolis.
The latest earnings report by $VZ shows how it is losing customers despite offering the unlimited data plans, a record for the company.
$BEBE is closing down all its stores by the end of May.
$WFC agreed to hike its payout in a class-action settlement over unauthorized accounts by $32 million to $142 million for its retail sales practices. The settlement will now include customers who were impacted as early as May 2002.